48 employees
Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.
2021
$50M
from 1 investors over 1 rounds
Belharra Therapeutics raised $50M on January 4, 2023
Investors: Versant Ventures